A bipartisan group of lawmakers plans to introduce legislation aimed at breaking up pharmacy benefit managers, requiring them to divest their pharmacy businesses within three years. This move, driven by ongoing scrutiny, could significantly impact the revenue of these companies and improve patient experiences.In a groundbreaking initiative, Eli Lilly will begin studying its GLP-1 obesity treatments, including Zepbound, as potential therapies for alcohol and drug addiction. Emerging research indicates these drugs may suppress cravings not only for food but also for other substances, marking a first for major drugmakers in this area.
